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nist RU486 (mifepristone) was accomplished by an upregula-
tion of PR-A expression in our study. We conclude that gesta-
genic effects on HUVECs independent of modulators are 
mediated via the PR-A.  Copyright © 2009 S. Karger AG, Basel 
 Introduction 
 Vascular endothelial cells are involved in the regula-
tion of angiogenesis, inflammatory responses, vascular 
tone and permeability. Impaired endothelial function 
leads to increased cardiovascular risk  [1] . In females, en-
dothelial dysfunction gradually ensues after the meno-
pause  [2] , and is associated with disturbed dilatation  [3] , 
decline in endothelial nitric oxide synthase (eNOS) activ-
ity and nitric oxide (NO) bioavailability as well as abnor-
mal endothelial morphology  [4, 5] . These functional al-
terations of endothelial cells contribute to the increased 
risk of cardiovascular diseases seen in postmenopaus-
al women  [6] . The incidence of coronary heart disease 
(CHD) in premenopausal women is significantly lower 
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 Abstract 
 Effects of female steroid hormones on endothelial cells are 
gaining increased importance due to several studies on the 
effects of hormonal treatment on cardiovascular risk. Recent 
data argue for an improvement of endothelium-derived
relaxation and impaired vascular contraction by estradiol, 
whereas progesterone and testosterone might entail con-
trary effects. So far, gestagenic influence on endothelial cell 
physiology is poorly understood. Human umbilical vein en-
dothelial cells (HUVECs) exposed to the female sex hormones 
estradiol and progesterone show expression of estrogen
receptor-  (ER  ) and progesterone receptor A (PR-A), and 
are negative for ER  and PR-B. The aim of this study was to 
analyze the expression and stimulation of PR-A and -B in
HUVECs after stimulation with progesterone and PR antago-
nists that are commercially available. PR-B expression or up-
regulation was abrogated after application of progesterone 
or antagonists to HUVECs. Expression of PR-A could be sig-
nificantly upregulated with progesterone and mifepristone. 
Unexpectedly, stimulation with the progesterone antago-
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than in age-matched men with similar risk profiles and 
increases after menopause  [7–9] .
 With regard to hormonal treatment (HT) in post-
menopausal women, progesterone is generally co-admin-
istered with estrogen to prevent endometrial cancer by 
opposing the proliferative effect of estrogens. So far, the 
influence of the administered progestagens on cardiovas-
cular function and development of atherosclerosis re-
mains controversial  [10, 11] . However, HT has been re-
garded as an effective tool to protect postmenopausal 
women from CHD  [12] . Until now, major randomized 
clinical trials have failed to confirm the cardiovascular 
advantages of HT  [13] .
 The Heart and Estrogen/Progestin Replacement Study 
showed that the co-administration of medroxyprogester-
one acetate (MPA) with conjugated equine estrogen (CEE) 
did not reduce the rate of events in postmenopausal wom-
en with established CHD, yet the treatment did increase 
the rate of thromboembolic events and gallbladder dis-
ease  [14–18] .
 The Women’s Health Initiative trial showed that HT 
combined with CEE and MPA was associated with a non-
significant increase in CHD in postmenopausal women, 
whereas women in the sister cohort, receiving CEE alone, 
showed a nonsignificant decrease in coronary events, 
along with a significant reduction in a composite out-
come of CHD events in younger women  [19, 20] .
 However, progesterone or other synthetic progestins 
have variable influences on endothelial function. For ex-
ample, natural progesterone increases endothelial NO 
production, whereas MPA is devoid of such action  [21] . In 
nonhuman primates, MPA has been shown to interfere 
with the atheroprotective effects of estrogens, which was 
not encountered with natural progesterone  [22, 23] . In 
support of these observations, discrepant effects of pro-
gestins have also been described in other tissues  [24] .
 A diversity of progesterone receptor (PR) activators 
and inhibitors exists with different potential to bind to 
PR-A, PR-B or both. In our study, we analyzed the expres-
sion of PR-A and PR-B in human umbilical vein endothe-
lial cells (HUVECs) after stimulation with progesterone 
and its antagonist mifepristone with specific monoclonal 
antibodies by immunocytochemistry. 
 Material and Methods 
 Cell Culture 
 HUVECs were obtained from Promocell (Heidelberg, Germa-
ny) at passage 2 or 3. The cells were cultivated in phenol red free 
endothelial cell growth medium (ECGM) (Customer formula-
tion, Promocell, Heidelberg, Germany). ECGM contained 10% 
fetal bovine serum, 1.0 mg/ml hydrocortisone, 0.1 ng/ml endo-
thelial growth factor, 1.0 ng/ml basic fibroblast growth factor and 
2 ml endothelial cell growth substrate as well as 5 ml streptomycin 
(Biochrom AG, Berlin, Germany) and 5 ml amphotericin B (Bio-
chrom) in 500 ml medium. 
 HUVECs were used for experiments between passages 3 and 4. 
All cell cultures were maintained in a humidified 5% CO 2 atmo-
sphere at 37 ° C. HUVECs were incubated with progesterone and 
mifepristone in different concentrations (0–100 nmol/ml;
 table 1 ) and cultivated for up to 72 h on chamber slides (Nunc, 
 Wiesbaden, Germany). These concentrations are related to physio-
logical progesterone concentrations in pregnant human females. 
Cells were fixed with methanol/ethanol (50/50%; Merck, Darm-
stadt, Germany). The Human Investigation Review Board of the 
Ludwig Maximilian University Munich approved the study.
 Immunocytochemistry 
 Expression of PR-A was analyzed by using a specific monoclo-
nal antibody (1A6, Mouse IgG1, 1: 50, Immunotech, Prague, Czech 
Republic) and the ABC staining method (Vectastain Elite mouse-
IgG-Kit, Vector, Burlingame, Calif., USA). Staining intensity was 
graded by using a semiquantitative score by counting the absolute 
percentage of positive-stained cells. 
 Two blinded, independent observers evaluated the specific 
immunocytochemical staining reaction without knowing the pri-
or evaluation of each specimen. In each condition, 6–9 indepen-
dent specimens were taken and evaluated independently.
 In brief, HUVECs were cultivated under sterile conditions in 
chamber slide cultures Quadriperm (Nunc) for up to 72 h, dried, 
wrapped and stored at –80 ° C as described earlier  [25] . After 
thawing, cells were briefly fixed with formalin (Merck; 5% in 
PBS, 5 min). Slides were incubated in methanol/H 2 O 2 (30 min) 
to inhibit endogenous peroxidase activity, washed in PBS
(5 min) and treated with goat serum (20 min, room temperature, 
RT) to reduce nonspecific background staining. Incubation 
with the primary anti-PR-A antibody (1A6, Mouse IgG1, 1: 50, 
Immunotech) was done overnight at 4 ° C. Sections were then 
incubated with the biotinylated secondary anti-mouse antibody 
(1 h, RT) and avidin-biotinylated peroxidase (45 min, RT). Be-
tween each step, the sections were washed with PBS (pH 7.4), 
three times. Peroxidase staining reaction was done with diami-
nobenzidine/H 2 O 2  (1 mg/ml; 5 min) and stopped in tap water 
(10 min). Sections were counterstained in hematoxylin (1 min) 
and then coverslipped. In controls, the primary antibody was 
replaced with preimmune mouse serum. Positive (MCF-7 breast 
cancer cell line) and negative control cells (MDA-MB231), both 
from American Type Culture Collection (Manassas, Va., USA), 
for PR-A staining were always included. The slides were finally 
Table 1. Substances used for stimulation of PR-A
Substance Dilution Source
Progesterone, nmol/ml 0.1–100 Sigma-Aldrich
Mifepristone, nmol/ml 0.1–100 Roussel–Uclaf
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embedded in mounting buffer and examined with a Zeiss Axio-
phot photomicroscope (Carl Zeiss, Jena, Germany). The extent 
of PR expression was determined in a blinded fashion in one run 
with identical staff, equipment, and chemicals. 
 From each section, 5 digital pictures were taken at random of 
different places of stained HUVECs ( ! 200 magnification; 3CCD 
color camera; Axiocam) and examined with a Zeiss Axiophot 
photomicroscope. 
 Statistics 
 The SPSS/PC software package (SPSS, Chicago, Ill., USA) ver-
sion 15.0 and 16.0 was used for collection, processing, and statis-
tical data analysis. Statistical analysis was performed using the 
nonparametric Mann-Whitney U signed rank test for compari-
son of the means. p  ! 0.05 values were considered statistically 
significant.
 Results 
 Progesterone 
 Progesterone acts as a natural PR ligand (PR-A, PR-B). 
HUVECs stimulated with 100 pmol/ml and 1, 10, and 100 
nmol/ml progesterone, respectively, showed expression 
of PR-A after cultivation for up to 72 h ( fig. 1 a–e). Sig-
nificantly elevated PR-A expression could be observed by 
administration of 10 and 100 nmol/ml progesterone, as 
described (p  ! 0.05;  fig. 1 f).
 Mifepristone 
 Unexpectedly, administration of the PR antagonist 
RU486 led to an upregulation of PR-A expression.
HUVECs stimulated with 1, 10, and 100 nmol/ml mife-
pristone showed significant upregulation of PR-A in all 
cases compared with nonstimulated controls (p  ! 0.05, 
respectively;  fig. 2 ). 
 Discussion 
 Recently, basic findings on the expression of estrogen 
receptor (ER) and PR in HUVECs were published, indi-
cating the lack of ER  and PR-B expression in HUVECs 
 [25] .
 In our study, we were able to demonstrate that proges-
terone acts as an activator on endothelial cells and is able 
0
20
40
60
80
100
120
PR
-A
 (%
)
100 10 1 0.1
* p = 0.043 * p = 0.043
Progesterone (nmol/ml)
Control
a b c
d e f
 Fig. 1.  a PR-A expression in unstimulated HUVECs.  ! 10.  b PR-A 
expression in HUVECs after 0.1 nmol/ml stimulation with pro-
gesterone.  ! 10.  c PR-A expression in HUVECs after 1.0 nmol/
ml stimulation with progesterone.  ! 10.  d PR-A expression in 
HUVECs after 10 nmol/ml stimulation with progesterone.  ! 10. 
 e PR-A expression in HUVECs after 100 nmol/ml stimulation 
with progesterone.  ! 10.  f PR-A expression in HUVECs after in-
cubation with progesterone. 
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to upregulate PR-A expression in a dose-dependent man-
ner. In contrast to former studies, PR antagonist RU486 
also led to an upregulation of PR-A expression.
 The cellular effects of gestagens are mediated by bind-
ing to nuclear receptors (PR) which activate transcription 
of genes involved in cellular growth control. So far, endo-
thelial effects of gestagens are poorly understood and, as 
compared with data on estrogenic influences on endo-
thelial cells, also poorly investigated. Fu et al. [26] inves-
tigated effects of progesterone and MPA on actin remod-
eling, moesin activation and cell movement in human 
endothelial cells. They were able to show that both gesta-
gens regulate endothelial cell movement by rapidly sig-
naling to the actin-binding protein moesin and to the 
actin cytoskeleton. 
 To further study the effects of gestagens on vascular 
function, Hermenegildo et al. [27] studied the effects of 
progesterone and MPA on prostacyclin production in 
HUVECs. Both gestagens significantly increased prosta-
cyclin release in a time- and dose-dependent manner by 
enhancing Cox-1 and Cox-2 expression and activities.
 In contrast to our recent findings on the lack of PR-B 
expression on HUVECs, Tatsumi et al. [28] described PR-
A and PR-B mRNA expression on HUVECs. The authors 
investigated the effect of progesterone, MPA, norethin-
drone acetate, levonorgestrel as well as dienogest on cy-
tokine-stimulated HUVEC expression of adhesion mol-
ecules. However, progesterone or dienogest did not af-
fect IL-1  -stimulated ICAM-1 or VCAM-1 expression, 
whereas the other gestagens did.
 Additionally, concomitant addition of mifepristone 
blocked the gestagen-induced increase in adhesion mol-
ecules. They concluded that dienogest unlike other syn-
thetic progestins lacks the stimulatory effect on cell adhe-
sion molecules  [28] . We were able to show that HUVEC 
stimulation with increasing amounts of RU486 leads to 
an upregulation of PR-A in a dose-dependent manner. 
Our data implicate that RU486 only acts as a PR antago-
nist in the presence of PR activators like progestone. 
 The Women’s Health Initiative trial reported an excess 
of heart diseases in postmenopausal women receiving 
MPA. Therefore, Simoncini et al. [21] investigated the ef-
fects of progesterone, MPA, dydrogesterone and its me-
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 Fig. 2.  a PR-A expression in unstimulated HUVECs.  ! 10.  b PR-A 
expression in HUVECs after 0.1 nmol/ml stimulation with mife-
pristone.  ! 10.  c PR-A expression in HUVECs after 1.0 nmol/
ml stimulation with mifepristone.  ! 10.  d PR-A expression in 
HUVECs after 10 nmol/ml stimulation with mifepristone.  ! 10. 
 e PR-A expression in HUVECs after 100 nmol/ml stimulation 
with mifepristone.  ! 10.  f PR-A expression in HUVECs after in-
cubation with mifepristone. 
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tabolite 20-a-dihydrogesterone on endothelial synthesis 
of NO, and characterized the signaling events recruited 
by these compounds. In contrast to dydrogesterone, pro-
gesterone and 20-a-dihydrogesterone, MPA did not trig-
ger eNOS enzymatic activation and decreased the extent 
of eNOS induction by estradiol. The authors concluded 
that their findings support the concept that synthetic 
progestins act differently on vascular cells and that hor-
monal preparations may differ in their cardiovascular ef-
fects  [29] .
 Studies on the effects of HT in postmenopausal wom-
en indicate procoagulant effects of gestagens and estro-
gens. To further study the effects of gestagens on hemo-
stasis, Zerr-Fouineau et al. [30] investigated whether pro-
gestins affect the formation of NO in endothelial cells 
and examined the underlying mechanism. 
 Certain progestins, including MPA, reduced the anti-
aggregatory effect of endothelial cells by decreasing the 
expression of eNOS and the formation of NO in endothe-
lial cells; an effect that is mediated via activation of glu-
cocorticoid receptors.
 In summary, our study showed that progesterone is 
able to upregulate PR-A expression in a dose-dependent 
manner and that the PR antagonist mifepristone also acts 
as a PR activator when administered solely.
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